featured
PCSK9 Inhibitor Price Reduction Essential for Cost-Effectiveness
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Updated Cost-Effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
JAMA 2017 Aug 22;318(8)748-750, DS Kazi, J Penko, PG Coxson, AE Moran, DA Ollendorf, JA Tice, K Bibbins-DomingoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.